Skip to main content

Kisspeptin-10 vs Cerebrolysin

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Kisspeptin-10

Kisspeptin-10 is the active fragment of kisspeptin, a hormone that plays a crucial role in initiating puberty and regulating reproductive function. It acts upstream of GnRH in the hypothalamic-pituitary-gonadal axis.

Full details →

Cerebrolysin

Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from purified pig brain proteins. It is approved in many countries for stroke, traumatic brain injury, and dementia.

Full details →

Side-by-Side Comparison

AspectKisspeptin-10Cerebrolysin
MechanismBinds to KISS1R receptors in the hypothalamus, stimulating GnRH neurons to release GnRH. This triggers the downstream cascade of LH, FSH, and sex hormone production.Contains multiple neurotrophic factors that promote neuroplasticity, reduce neuronal apoptosis, and support synaptic function. Has both neurotrophic and neuroprotective properties.
Typical DosageResearch protocols vary widely. Studies have used IV boluses of 1-10mcg/kg or subcutaneous administration. Clinical applications still being developed.Clinical dosing: 10-30ml IV daily for acute conditions. Research use: 5-10ml IM daily for cognitive enhancement. Treatment courses typically last 10-20 days.
AdministrationIV or subcutaneous injection. Has very short half-life requiring frequent administration or continuous infusion for sustained effects.Administered via intramuscular or intravenous injection. IV administration is typically used in clinical settings. IM can be used for research purposes.
Side EffectsLimited data. May cause flushing, increased heart rate, and changes in libido. Generally well-tolerated in studies.Generally well-tolerated. May cause dizziness, headache, sweating, or injection site reactions. Rare cases of agitation or confusion.
Best For

Key Differences

Unique to Kisspeptin-10:

Unique to Cerebrolysin:

Ready to Learn More?